Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study

被引：26

作者：

Woyach, Jennifer A. ^{[1
]}

Flinn, Ian W. ^{[2
]}

Awan, Farrukh T. ^{[3
]}

Eradat, Herbert ^{[4
]}

Brander, Danielle ^{[5
]}

Tees, Michael ^{[6
]}

Parikh, Sameer A. ^{[7
]}

Phillips, Tycel J. ^{[8
]}

Ghori, Razi ^{[9
]}

Reddy, Nishitha M. ^{[9
]}

Farooqui, Mohammed Z. H. ^{[9
]}

Byrd, John C. ^{[10
]}

Stephens, Deborah M. ^{[11
]}

机构：

[1] Ohio State Univ, Columbus, OH 43210 USA

[2] Sarah Cannon Res Inst, Nashville, TN USA

[3] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA

[4] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[5] Duke Univ, Duke PDC, Durham, NC USA

[6] Colorado Blood Canc Inst, Denver, CO USA

[7] Mayo Clin, Rochester, MN USA

[8] Univ Michigan, Rogel Canc Ctr, Ann Arbor, MI 48109 USA

[9] Merck & Co Inc, Rahway, NJ 07065 USA

[10] Univ Cincinnati, Coll Med, Cincinnati, OH USA

[11] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA

来源：

BLOOD | 2022年 / 140卷

关键词：

D O I：

10.1182/blood-2022-163596

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：7004 / 7006

页数：3

共 13 条

[1] Preliminary Efficacy and Safety of MK-1026, a Non-Covalent Inhibitor of Wild-Type and C481S Mutated Bruton Tyrosine Kinase, in B-Cell Malignancies: A Phase 2 Dose Expansion Study
Woyach, Jennifer A.
Flinn, Ian W.
Awan, Farrukh T.
Eradat, Herbert
Brander, Danielle M.
Tees, Michael
Parikh, Sameer A.
Phillips, Tycel
Wang, Wayne
Reddy, Nishitha M.
Farooqui, Mohammed Z. H.
Byrd, John C.
Stephens, Deborah M.
BLOOD, 2021, 138
[2] Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible Bruton'S Tyrosine Kinase Inhibitor, Vecabrutinib, in B-Cell Malignancies
Allan, John N.
Patel, Krish
Mato, Anthony R.
Wierda, William G.
Ibarz, Javier Pinilla
Choi, Michael Y.
O'Brien, Susan M.
Sharman, Jeff P.
Shadman, Mazyar
Gladstone, Douglas E.
Davids, Matthew S.
Pagel, John M.
Ward, Renee
Acton, Gary
Taverna, Pietro
Fox, Judith A.
Furman, Richard R.
Brown, Jennifer R.
BLOOD, 2019, 134
[3] Zanubrutinib in patients with previously treated B-cell malignancies intolerant of previous Bruton tyrosine kinase inhibitors in the USA: a phase 2, open-label, single-arm study
Shadman, Mazyar
Flinn, Ian W.
Levy, Moshe Y.
Porter, Ryan F.
Burke, John M.
Zafar, Syed F.
Misleh, Jamal
Kingsley, Edwin C.
Yimer, Habte A.
Freeman, Benjamin
Rao, Subramanya S.
Chaudhry, Arvind
Tumula, Praveen K.
Gandhi, Mitul D.
Manda, Sudhir
Chen, Dih-Yih
By, Kunthel
Xu, Linlin
Liu, Ye
Crescenzo, Rocco
Idoine, Adam
Zhang, Xiaoping
Cohen, Aileen
Huang, Jane
Sharman, Jeff P.
LANCET HAEMATOLOGY, 2023, 10 (01): : E35 - E45
[4] Efficacy and safety of tirabrutinib, highly selective Bruton's tyrosine kinase inhibitor, for oral treatment of pemphigus: a multicenter, open-label, uncontrolled, single-arm phase 2 study
Yamagami, J.
Ujiie, H.
Aoyama, Y.
Ishii, N.
Tateishi, C.
Ishiko, A.
Ichijima, T.
Hagihara, S.
Hashimoto, K.
Amagai, M.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2021, 141 (10) : S155 - S155
[5] Part a Efficacy and Safety of Oral Bruton Tyrosine Kinase Inhibitor (BTKi) Rilzabrutinib in Patients with Warm Autoimmune Hemolytic Anemia (wAIHA): Multicenter, Open-Label, Phase 2b Study
Cooper, Nichola
Kuter, David J.
Frederiksen, Henrik
Han, Bing
Chen, Frederick
Barcellini, Wilma
Cid, Joan
Broome, Catherine M.
Vara, Miriam
Mazumder, Amitabha
Lucchesi, Alessandro
Zhao, Xin
Risitano, Antonio M.
Sawhney, Sumit
Hill, Quentin A.
Jayawardene, Deepthi
Diab, Remco
Zhao, Jing
Daak, Ahmed
BLOOD, 2024, 144 : 3836 - 3837
[6] A phase 1 open-label, safety, pharmacokinetic, and preliminary efficacy study of STRO-001, an anti-CD74 antibody drug conjugate, in patients with advanced B-cell malignancies.
Krishnan, Amrita Y.
Shah, Nina
Spira, Alexander I.
Kaufman, Jonathan L.
Niesvizky, Ruben
Shah, Nirav Niranjan
Burke, John M.
Popplewell, Leslie
Martin, Thomas G.
Cheung, Julee
Matheny, Shannon L.
Leonard, John Paul
Molina, Arturo
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[7] Preliminary Safety, Pharmacokinetic, and Pharmacodynamic Results from a Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor (BTKi), Vecabrutinib, in B-Lymphoid Malignancies
Allan, John N.
Wierda, William G.
Patel, Krish
O'Brien, Susan M.
Mato, Anthony R.
Davids, Matthew S.
Furman, Richard R.
Pagel, John M.
Fox, Judith A.
Ward, Renee
Taverna, Pietro
Brown, Jennifer R.
BLOOD, 2018, 132
[8] Phase 1 open-label dose escalation study of the dual SYK/JAK inhibitor cerdulatinib (PRT062070) in patients with relapsed/refractory B-cell malignancies: Safety profile and clinical activity
Flinn, Ian
Hamlin, Paul A.
Strickland, Donald K.
Pandey, Anjali
Birrell, Matt
Coffey, Greg
Leeds, Janet
Curnutte, John T.
Burger, Jan Andreas
Wagner-Johnston, Nina D.
Patel, Manish R.
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[9] Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study
Jun Guo
Yiran Huang
Xu Zhang
Fangjian Zhou
Yinghao Sun
Shukui Qin
Zhangqun Ye
Hui Wang
Annette Jappe
Patrick Straub
Nicoletta Pirotta
Sven Gogov
BMC Cancer, 13
[10] Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study
Guo, Jun
Huang, Yiran
Zhang, Xu
Zhou, Fangjian
Sun, Yinghao
Qin, Shukui
Ye, Zhangqun
Wang, Hui
Jappe, Annette
Straub, Patrick
Pirotta, Nicoletta
Gogov, Sven
BMC CANCER, 2013, 13

← 1 2 →